J&J's Janssen un­veils PhII ul­cer­a­tive col­i­tis da­ta for Trem­fya com­bo, look­ing to ex­pand the drug's foot­print

As J&J’s Janssen has worked to ex­pand the use of Trem­fya over the past few years, its lat­est da­ta show that it is poised to en­gage in treat­ment for ul­cer­a­tive col­i­tis.

On Mon­day, the com­pa­ny dis­played da­ta from a Phase IIa clin­i­cal tri­al for adults with mod­er­ate to se­vere UC who re­ceived a 12-week ther­a­py of Trem­fya, al­so known as guselkum­ab, and goli­mum­ab. That was then fol­lowed by a tran­si­tion on­ly to Trem­fya.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER